StockNews.AI

NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei

StockNews.AI • 2 days

ABL BioVisara
High Materiality8/10

Information

ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge o...

Original source

AI Summary

Fu Wei, Executive Chairman of NovaBridge, plans to purchase up to $5 million in ADSs, starting January 15, 2026. This reflects confidence in the company's growth potential, supported by promising Phase 1b trial results for their drug givastomig targeted at metastatic gastric cancer.

Sentiment Rationale

Insider buying often signals positive sentiment; historical trends show stocks frequently rise post-strong clinical data announcements.

Trading Thesis

Buy NBP for potential gains from positive clinical data and insider confidence.

Market-Moving

  • Insider buying could indicate future price appreciation.
  • Positive Phase 1b results may attract investor interest and stock price growth.
  • Execution of the planned ADS purchases can provide upward price momentum.
  • Further clinical developments could lead to valuation re-ratings.

Key Facts

  • Fu Wei plans to purchase up to $5M of NovaBridge's ADSs.
  • Purchase execution started on January 15, 2026.
  • Positive results from Phase 1b trials for givastomig.
  • NovaBridge believes it is well-positioned for growth.
  • Givastomig targets Claudin 18.2-positive gastric cancer.

Companies Mentioned

  • NovaBridge Biosciences (NBP): Insider buying signals strong future prospects and confidence.

Corporate Developments

This fits under 'Corporate Developments' as it highlights executive confidence through insider buying and key clinical data supporting future growth.

NovaBridge Biosciences Announces $5M Open Market Purchases by Fu Wei

Rockville, MD, January 20, 2026 – NovaBridge Biosciences (Nasdaq: NBP), a global leader in biotechnology, has revealed that Fu Wei, the Executive Chairman of the Board, plans to acquire up to $5 million in American Depository Shares (ADSs) of the Company. This strategic move commenced on January 15, 2026, and continues as of the date of this announcement.

Details of the Open Market Purchases

Fu Wei intends to execute these purchases through a controlled entity, which means that NovaBridge cannot predict the exact number of ADSs to be bought or the timeframe of these acquisitions. “2025 was a defining year for NovaBridge,” stated Fu Wei. “We executed a new business strategy and built a truly global platform... We believe we are well-positioned for the next phase of growth.”

Significance of Recent Developments

NovaBridge has been making headlines recently with the release of promising data from Phase 1b trials regarding the drug givastomig, which targets metastatic gastric cancer. This advancement reinforces the company’s commitment to innovative solutions in the biotechnology sector.

About NovaBridge Biosciences

NovaBridge Biosciences focuses on accelerating access to breakthrough medical therapies. With a robust pipeline, the company aims to address critical health needs through effective and innovative strategies. Key assets include:

  • Givastomig: A potential best-in-class Claudin 18.2 x 4-1BB bispecific antibody.
  • VIS-101: A leading bifunctional biologic targeting VEGF-A and ANG2, currently in a Phase 2 study for wet age-related macular degeneration.
  • Ragistomig: Developed in partnership with ABL Bio, this bispecific antibody is aimed at solid tumors.
  • Uliledlimab: An anti-CD73 antibody focusing on cancer's immunosuppressive environment.

Forward-Looking Statements

This announcement includes forward-looking statements identified by terms such as "will," "believes," and "intends." These statements address potential market risks and uncertainties that may affect the actual outcomes of the Company’s plans, including:

  • Market conditions affecting the price and demand for NBP shares.
  • Clinical development and safety results of drug candidates.
  • Regulatory decisions by authorities regarding drug approvals.
  • The commercialization success of NBP’s drug candidates.

NovaBridge is committed to transparency and will update stakeholders as necessary regarding developments that could impact the Company’s future.

Contact Information

For investor inquiries, please contact:

Related News